Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

November 13, 2025

OTC Pink Market US Health Care Biotechnology earnings 26 min

Earnings Call Speaker Segments

Ed Berg

executive
#1

Good afternoon, everyone, and thank you for being on today's call. Joining us from Vaxart are Steven Lo, our Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James Cummings, Chief Medical Officer; and Jeroen Grasman, Chief Financial Officer. Before we begin, please note that during this conference call, Vaxart may make forward-looking statements. These include statements about the company's financial results, financial guidance, future business strategies and operations, and product development and regulatory progress, including statements regarding its ongoing or planned clinical trials. Various significant elements might lead to real outcomes diverging considerably from what gets covered within these projections, such as unpredictability intrinsic to drug testing and the approval pathway, plus additional hazards outlined under the Risk Factors portion of Vaxart's latest annual filing on Form 10-K, alongside subsequent periodic submissions made to the SEC. Following today's call, Vaxart assumes no duty to revise any forward-looking remarks. At this point I'll hand things over to Steven Lo. Steve?

Steve Lo

executive
#2

Thanks, Ed, and I'm glad all of you could join us this afternoon. To begin today's call, I'll give everyone a rundown of the business, and after that James and Sean will take over to bring you the latest on our programs. Next, Jeroen will walk us through the financials. Finally, I'll make some brief closing comments, and then we'll open things up for your questions. First, let's turn to our COVID-19 clinical program. Last week, we were happy to announce a collaboration with Dynavax that creates substantial value — Dynavax being a commercial stage biopharmaceutical company that has shown it can successfully bring novel vaccines to market. Per the terms of this deal, Vaxart could receive up to $700 million altogether in license fees, regulatory payments, and milestone payments, along with royalties, tied to our oral COVID-19 vaccine candidate. For both the company and this program, that marks a significant achievement — it validates what our platform can do and provides crucial nondilutive funding to keep the program moving forward. Several key provisions of the agreement are listed below. Dynavax is obligated to pay Vaxart a $25 million upfront license fee, and it will also invest $5 million in equity in Vaxart, at a price per share that carries a premium over market, in line with the securities purchase agreement's terms. Combined with the cash we currently hold, our runway now extends through the second quarter of 2027. Under the terms, Dynavax gets a global exclusive license to create and sell oral COVID-19 vaccines that rely on Vaxart's delivery platform. Until the current Phase IIb clinical trial wraps up, plus the end of Phase II meeting with the FDA that follows, Vaxart keeps complete operational and financial responsibility for the oral COVID-19 vaccine program. Also, after the Phase IIb clinical trial results come in, Dynavax would owe Vaxart an additional $50 million if Dynavax decides to assume responsibility for further clinical development of the oral COVID-19 vaccine program. Finally, should Dynavax choose to take over further work on the oral COVID-19 program, Vaxart may become entitled to collect up to $195 million tied to future regulatory milestones, up to $425 million tied to future net sales milestones, and graduated royalties, calculated at low to mid-teen rates, on any eventual net sales of our oral COVID-19 vaccines. For Vaxart as a business, we regard this partnership as hugely significant. It lengthens the amount of time our cash can fund operations, and past that, it reflects the potential of our oral vaccine platform, which might prove to be a key point of distinction from competing methods of vaccine delivery. James will cover the specifics of our Phase IIb progress in a moment, but we're still set to share multiple datasets in 2026. Dynavax has noted that COVID-19 continues to circulate widely, with infections, hospitalizations and fatalities still occurring, and that fresh options are needed — a view we share. Right now, deals in the vaccine field are scarce, and we value Dynavax's funding and know-how, which can help push this program toward approval. Partnering with Dynavax will also leave Vaxart better positioned for later-stage development across other indications. This is, once again, a major step forward for our company. And we're grateful that Dynavax agrees with our belief that this novel approach of ours might one day reshape public health around the world and completely change how distribution and administration are done; we're eager to provide future updates about our progress and this collaboration. Now onto our norovirus program. As we mentioned before, we were happy to announce positive Phase I top line results for our second-generation constructs, showing that this vaccine technology generated considerably more robust antibody responses than our first-generation constructs did. Following that positive top line data update, we've given presentations at several medical conferences, calling attention to the statistically significant rises in GI.1 and GII.4 norovirus blocking antibodies, along with other study analyses, which highlights the protection potential these new constructs offer. Sean is going to walk through more specifics of our compelling norovirus data in a moment. Around the world, norovirus remains a top cause of acute gastroenteritis, producing substantial morbidity and mortality in nations at every income level, especially among young children and older adults. With an economic burden exceeding $10 billion in the United States by itself, there's still a pressing need for a norovirus vaccine that is both safe and effective. We think our norovirus vaccine candidate could be first-in-class or best-in-class since, at present, no vaccines have been approved and other products under development lack the distinctive profile and delivery benefits that our platform offers; we're still eager to move this program forward and have kept talking with a number of interested parties since our last update. Although we're dedicated to locking in our partnership, please keep in mind that these talks depend on the other parties' time lines, not only on ours. Consequently, we now expect to begin the next clinical trial in 2026, assuming we get funding. In closing, across multiple initiatives, we're keen to continue demonstrating the strength of our oral vaccine efforts; having Dynavax on board as a collaborator means we can accelerate our COVID-19 work, contingent on 2 readouts in 2026 that could be quite robust; because our platform is designed to generate both systemic and mucosal protection, our oral pill vaccine has the potential to transform public health worldwide and fundamentally alter how distribution and administration are done. At this point I'll turn things over to Dr. Cummings, who will walk through our COVID-19 clinical program. James?

James Cummings

executive
#3

Thank you, Steve, and I appreciate all of you being on the call today. As Steve mentioned, we have achieved substantial advancement on the business development side for our oral pill vaccine candidate targeting COVID-19, having entered into an exclusive licensing arrangement with Dynavax. Our clinical development work on this asset is also continuing to move forward in meaningful ways. Back in August, we disclosed that we had received a stop work order from BARDA concerning our Phase IIb clinical trial that compares our oral pill vaccine for COVID-19 against an mRNA injectable vaccine that is commercially available; that directive halted enrollment while still permitting us to carry on activities tied to the per protocol follow-up of participants who had already been given a vaccine. During October, we shared that BARDA would keep supplying funding for follow-up covering the roughly 5,400 subjects who had enrolled, which breaks down as 400 subjects within the sentinel cohort plus approximately 5,000 subjects in the KP.2 cohort that were enrolled in the trial. It is our belief that data from the trial generated by these enrolled participants will yield valuable insights along with a robust evidence foundation that might potentially move our COVID program forward. Let me remind you that this study's primary endpoint is the relative efficacy of our oral pill vaccine versus the mRNA vaccine across 12 months post vaccination. Efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events within each cohort will all be measured in the trial. We are still on schedule to report 12-month top line data from the 400-participant sentinel cohort during the first quarter of 2026, and to report 12-month top line data covering all participants in the fourth quarter of 2026. Beyond potentially advancing our COVID-19 program, we believe this trial's results additionally bolster our oral pill vaccine platform technology and help guide development of our other pipeline assets. I will now hand the call over to Dr. Sean Tucker for an update regarding those assets. Sean?

Sean Tucker

executive
#4

Thanks, James. During Q3, at the Ninth International Calicivirus Conference, we shared further Phase I results that back the possible efficacy of our oral pill norovirus vaccine candidate from the second generation. Those results demonstrated, following a single tablet for each strain at a high dose of the second-generation candidates, a 25-fold rise over baseline in the GII.4 fecal IgA response along with a tenfold rise over baseline in the GI.1 fecal IgA response. Following a single tablet for each strain at a low dose of the second-generation candidates, the results also demonstrated an eightfold rise over baseline in the GII.4 fecal IgA response along with a sevenfold rise over baseline in the GI.1 fecal IgA response. The Phase I study lacked the power to establish superiority through statistical methods, yet the fecal IgA gains seen at the high dose with the second-generation constructs compared favorably against the gains seen at that same high dose level with the first-generation constructs. As a reminder, findings from the Phase II challenge study of our first-generation constructs pinpointed fecal IgA as a key correlate of protection against norovirus infection. The favorable fecal IgA findings with our second-generation construct, taken together with the serum responses announced earlier, strongly indicate that the second-generation constructs bring about immunological responses that are much more robust than those from our first-generation constructs. In our view, this could translate into better protection for our second-generation constructs. As discussed previously, this program is set to move into its next clinical study once a partnership or other funding is in place; given how successfully our partnership with Dynavax for our COVID-19 program concluded, norovirus stays a highly attractive opportunity, and we keep concentrating on obtaining resources to move our second-generation norovirus program forward; for the possible timing of the next clinical trial, we are updating our guidance to a start in 2026. I'll now pass the call to Jeroen for a short discussion of our financials. Jeroen?

Jeroen Grasman

executive
#5

Thanks, Sean. Today's press release lays out the specifics of our financial results for the third quarter of 2025. For that quarter of 2025, revenue came in at $72.4 million, up against $4.9 million for the same period in 2024. Most of the third quarter 2025 revenue stemmed from the BARDA contract that was awarded in June 2024. As for the third quarter of 2024, its revenue largely came from a different BARDA contract, one granted in January of 2024. When the third quarter closed, Vaxart held cash, cash equivalents and investments totaling $28.8 million. Under our present plan, which takes into account proceeds from the license agreement we have with Dynavax that arrived following the quarter's close, Vaxart anticipates a cash runway extending into the second quarter of 2027. Vaxart will keep pushing hard to find strategic partnerships, to chase additional nondilutive funding options, and to handle our expenses carefully, all so we can lengthen that cash runway. At this point I'll hand the call back to Steve for his closing remarks.

Steve Lo

executive
#6

Appreciate that, Jeroen. Just to sum things up, the whole team at Vaxart couldn't be more thrilled about the collaboration agreement with Dynavax covering our COVID-19 program. Having Dynavax behind us, along with their late-stage know-how, is going to make a real difference as we move this program forward. On top of that, this partnership gives even more validation to our oral vaccine platform, highlighting what it could do to transform global public health. We're eager to share several data readouts from our COVID Phase IIb trial in 2026. When it comes to our pipeline — norovirus, flu and HPV assets — the encouraging preclinical and clinical data behind them show just how broadly valuable our oral vaccine platform is. We're still in active conversations with a lot of interested parties regarding partnership opportunities across each of these programs, and we'll pass along updates on any developments once they're available. Before we get to your questions, a quick reminder to our listeners: we have a webcasted fireside chat on the schedule for Tuesday, November 18, at 4:30 p.m. Eastern Time. During that fireside chat, we're looking forward to tackling more of the questions stockholders have been asking us most often. Also, a reminder that you're welcome to send written questions to ir@vaxart.com; we'll try our hardest to answer as many of them as we can at the fireside chat. Because that fireside chat is coming up next Tuesday, we won't be taking written questions on today's call. Thanks to all of you for spending time with us today. Operator, please go ahead and open the line for questions.

Cheng Li

analyst
#7

Congrats on the advancement and on the Dynavax tie-up. We might have 2 questions. To start, could you explain why Dynavax chose to sign a deal at this point rather than hold off a few months to view the sentinel cohort data in early '26? And could you also give us some sense of what data they reviewed prior to possibly finalizing the deal? Then I have one more question after that.

Steve Lo

executive
#8

Thanks, Cheng, for asking. Sure. To begin with, we are, naturally, extremely thrilled about our partnership with Dynavax. As for what they examined, at a broad level, the first thing is the science behind the platform. There was considerable discussion regarding what this platform is capable of delivering, and everything we've described concerning oral delivery, mucosal immunity, and so forth. Beyond that, this timing suited both sides even prior to the data being available, given how well the two companies match. We're truly pleased to have a vaccine company with a proven track record that has guided a product through FDA approval and through commercialization. From a timing perspective, it simply came together very nicely, and we're happy they're with us. Regarding the data they might have reviewed — and James can certainly speak to this — we remain blinded to the clinical data. That said, in any partnership arrangement, there's a fair amount of due diligence. So we were actually glad they took their time, worked through the diligence, and ultimately felt quite comfortable proceeding with the deal. James, if you'd like to add something or restate the point that we are, indeed, blinded in the clinical trial, I'll leave that to you.

James Cummings

executive
#9

Appreciate it, Steve. Regarding the clinical trial that's running right now — it's double-blinded. That means neither we nor the people taking part know which product any of them got, and we're still gathering data from them. Top line data for the sentinel cohort should be ready in Q1 of 2026. As for the bigger KP.2 cohort — roughly 5,000 people — top line data will be ready once that study wraps up, at the end of its 12-month follow-up, which places us in Q4 of 2026. Up until then, since the study remains double blinded, there's nothing further we can say about it.

Cheng Li

analyst
#10

Understood, that clears things up. So I suppose my next thing is — given that extra money, say the upfront payments coming in from Dynavax — could you share how you're viewing the norovirus program? Is it possible you'd launch the Phase IIb trial on your own? And if that isn't feasible, how are you ranking the pipeline given this new funding?

Steve Lo

executive
#11

Sure. Cheng, appreciate you asking. Broadly speaking, first of all, it makes us glad to receive this validation from a vaccine company with a real track record — it confirms our technology holds solid value in the market. And clearly, when it comes to a COVID vaccine candidate, Dynavax holds the same belief we do that this remains a strong market opportunity. As for the rest of our assets — HPV, norovirus, and flu too — this has opened up chances for us to keep talking with possible partners about any one of them. So nothing has shifted in terms of priority, and that takes in norovirus as well: holding useful discussions with anybody keen on a partnership with us. Beyond that, Sean, who is seated right here, could back me up, I believe, on this: thanks to the platform being validated, some parties might now want to hand us their antigen to run on our platform. Sean, feel free to add anything further.

Sean Tucker

executive
#12

Absolutely. Yeah, considering how robust our clinical results are, and naturally, with the recent endorsement from our colleagues over at Dynavax across the bay, plenty of curiosity has emerged regarding the use of certain novel antigens alongside our platform. And naturally, those potential partnerships remain quite preliminary, though our dedication stays with the existing pipeline. Yet should an opportunity arise, we'd be thrilled to advance it.

Nabeel Nissar

analyst
#13

Nabeel here, sitting in for Roger. We've got maybe two items for you. What's your take on the COVID season this year, how it stacks up against the prior one, and what kind of market opportunity exists for something that's oral once again? Also, how do you view your product's strain — its capacity to handle a strain shift, which we've witnessed not only with COVID but earlier with norovirus?

Steve Lo

executive
#14

Thanks, Nabeel, for that. Sure, I'll offer a few broad thoughts on the market; and I believe the ideal individual to address strains and the ability to react to them would be James; but let me add one more point regarding our manufacturing. So I think everyone listening is aware that our clinical manufacturing takes place right here in South San Francisco. And when it came to the COVID trial, we felt quite good about being able to make product not only for the XBB strain but for the KP.2 strain as well. So as an organization, we consider ourselves to have been quite adaptable in manufacturing something for a strain in a very prompt fashion. I think you've also observed, regarding your first question about the COVID marketplace, correct, that it remains a sizable market. Of course, fewer people are getting the COVID shots these days. That might be due to what's being reported in the press; it might be due to side effects as they perceive them. It might simply be because it feels like a bit of a hassle to book an appointment, head to the pharmacy, and get the shot; and from where we sit, we provide plenty of advantages along with alternatives to that. So I think from our perspective, and Dynavax certainly assessed this too, that a solid market opportunity still exists when it comes to COVID. I'll hand things over to James. James, if you'd like to say a few words on strains and related matters.

James Cummings

executive
#15

Appreciate that, Steve, and I'm grateful for the question. I'd frame it as 2 points. First, regarding strain changes, our earlier work while developing this product demonstrated that we can achieve cross-reactivity — not only against the strain of interest, the one this product was designed for, but also against strains that are newly emerging. The upside of this — one advantage of this protocol — is that we're evaluating efficacy across a period of up to 12 months. Throughout that window, we're not just checking whether someone became ill or got infected by the virus and/or showed symptoms, but we're also examining which potential strains might appear. As everyone knows, coronaviruses are capable of adapting and shifting, or changing strain; therefore, across a 12-month span, our expectation is that we'll more than likely observe one strain in circulation, definitely within the United States, but truly worldwide. And — that represents some of the data we'll be reviewing as part of this study.

Sean Tucker

executive
#16

There's another point I want to mention, and once again, this is among the crucial aspects that we were able to show in a solid animal model: we demonstrated that when our vaccine generates those mucosal responses, it could affect how well the virus spreads to other people. So the overall health advantage it offers might be greater. And of course, since this platform comes as an oral pill, that fact makes it far more distinctive compared with the other options available.

Operator

operator
#17

Appreciate it. That wraps up the Q&A portion, and once more we'd like to express our gratitude for everyone taking part today. You're free to drop off the lines now. That brings our call to a close.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.